



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00	A2	(11) International Publication Number: WO 99/07418 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16589 (22) International Filing Date: 10 August 1998 (10.08.98) (30) Priority Data: 08/908,094 11 August 1997 (11.08.97) US (71) Applicant: ALLERGAN SALES, INC. [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US). (72) Inventors: OLEJNIK, Orest; 21121 Meander Lane, Trabuco Canyon, CA 92679 (US). HUGHES, Patrick, M.; 50 Cloudcrest, Aliso Viejo, CA 92656 (US). KENT, John, S.; 2816 Cliff Drive, Newport Beach, CA 92663 (US). (74) Agents: FISHER, Carlos, A. et al.; Allergan Sales, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: STERILE BIOERODIBLE IMPLANT DEVICE WITH IMPROVED BIOCOMPATABILITY AND METHOD (57) Abstract <p>A plantable device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.</p> <div data-bbox="826 1294 1289 1550" data-label="Image"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

STERILE BIOERODIBLE IMPLANT DEVICE WITH IMPROVED
BIOCOMPATABILITY AND METHOD

The present invention is generally related to implantable
5 devices and is more particularly directed to an implantable
prosthesis having improved biocompatibility. Still more
particularly, the present invention is directed to an
implantable device having improved biocompatibility while
providing systemic release of a therapeutic agent in tissue.

10

It should be appreciated that physiological compatibility
and biocompatibility are common problems for both implants for
providing a systemic, or local, release of the therapeutic
agent and for prosthesis, i.e., implants, utilized for
15 functional or cosmetic reasons, or both.

The functional biocompatibility of an implant or device,
is, of course, determined by the chemical and surface
properties of the implant and its components. The general
20 structure of a device, including mechanical strength,
elasticity, flexibility, fatigue resistance, chemical
inertness, impermeability to water, resistance to acid, etc.,
all contribute to biocompatibility which, of course, also
depends upon the type of tissue into which the implant is to
25 be inserted. Most importantly, the surface of the implant in
contact with body tissues should also exhibit resistance to
immunological attack, cell adhesion, pannus formation, etc.

Undesirable properties which can result from tissue
30 interacting with the surface may significantly affect the
efficiency of the implant and be counteractive to the intended
use of the implant in certain medical devices, for example,
sustained or controlled drug release devices.

The use of a sustained, or controlled release system has a well known advantage of providing an active agent at a relatively constant level of concentration in tissue. Sustained drug release systems have been utilized in a great number of applications including drug release into the vitreous for endophthalmitis and other vitreoretinal disorders with the use of antibiotics and a fungal agent, antineoplastic drugs and anti-inflammatory agents.

Unfortunately, in many instances, particularly where the implant is intended to remain in contact with tissue for extended periods of time, various problems associated with the physiological and chemical stability and compatibility with respect to various of the contacted tissues and biological fluids occurs. This is true even though the implant may function properly in its sustained or controlled release of the active agent.

For example, biomaterial such as a synthetic polymer, when contacted with blood, rapidly forms an adsorbed protein layer. Subsequently, conformational alterations and complexing of proteins which may occur which activate defense mechanisms such as coagulation, platelet adhesion, and aggregation, white cell adhesion, etc.

In eye tissue, an implant may cause superficial vascularization of the cornea with infiltration of granulation tissue. Biodegradable polymers may cause mild foreign body reactions which include inflammation in the vitreous.

Implanted biomaterials will cause a typical foreign body reaction with fibrinous membrane formation. A fibrinous membrane will surround and encapsulate the implant. Contraction of this fibrous capsule can range from transient pain to serious sequelae depending upon the location.

Fibrinous infiltration of the vitreous with a prominent inflammatory response can lead to traction retinal detachment, disruption of the retinal pigmented epithelium or breakdown of the blood retinal barrier. Tissue and organ adhesions may develop as a result of the fibrinous inflammation. Intraocular implants can also cause cataract formation. Iris-ciliary body adhesions would seriously effect the homeostasis of ocular tension. Implants may cause acute and chronic inflammation. Tissue necrosis and scarring may result as well as neovascularization. Biopolymers may often be antigenic and elicit allergic or other adverse events. In the case of an implantable material in the vasculature or heart thrombus formation and embolus may occur.

15 SUMMARY OF THE INVENTION

In accordance with one embodiment of the present invention, an implantable device is provided for systemic, or local, release of a therapeutic agent in tissue. The device generally includes a therapeutic agent along with a carrier sized for insertion into tissue in which the systemic release of a therapeutic agent is desired, the carrier including means for providing sustained or controlled release of the therapeutic agent.

25

In addition, retinoid means, present in the carrier, is provided for improving biocompatibility of the device in the tissue.

30 As will be described in detail hereinafter, this hereinbefore unrecognized property of a retinoid substantially reduces or prevents undesirable attributes which can result from tissue interacting with the surface of the implantable device.

More particularly, in accordance with the present invention, the retinoid means may comprise a retinoid receptor agonist and the therapeutic agent, carrier, and retinoid means, may be homogeneous. This homogeneity provides for ease
5 of manufacturing through the use of simple extrusion techniques or injection molding.

Specifically, in accordance with this embodiment of the present invention, the means for providing time release of the
10 therapeutic agent may comprise a biodegradable polymer, such as, for example, a poly(lactic acid) and poly(lactide-co-glycolide).

More particularly, in accordance with one embodiment of
15 the present invention, the carrier may be sized for implanting into a sclera and the retinoid receptor agonist may be a retinoid acid, for example, selected from the group of naturally occurring retinoids such as Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid)
20 and their synthetic and natural congeners. These would include but not be limited to the isomers all trans; 9-cis; 11-cis; 13-cis; 9, 11-dicis, and 11, 13-dicis as well as physiologically compatible ethers, esters, amides and salts thereof. The 7, 8-dihydro and 5, 6-dihydro congeners as well
25 as etretinate are also acceptable for the invention.

Compounds that intrinsically or upon metabolism possess the physiologic properties of retinoids are also included within the scope of this invention. These would include
30 synthetic and natural retinoid compounds having affinity to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs).

More particularly, the retinoid receptor agonist may be ethyl-6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate, or 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinic acid, or p-[(E)-2-(5,6,7,8-tetrahydro-, 5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid.

Corresponding to the device of the present invention, a method in accordance with the present invention for improving biocompatibility of an implant in tissue generally includes the steps of providing a therapeutic agent, providing a carrier sized for insertion into tissue in which release of the therapeutic agent is desired, incorporating a therapeutic agent into a carrier in a manner enabling sustained or controlled release of the therapeutic agent and incorporating a retinoid into the carrier in an amount effective for improving biocompatibility of the carrier in the tissue.

Another embodiment of the present invention includes an implantable device, specifically a surgically implantable prosthesis in combination with retinoid means for improving the biocompatibility of the prosthesis. More specifically, the retinoid means may be present in the form of a film on the prosthesis or, alternatively, bonded to a surface of the prosthesis. As hereinabove noted, the retinoid means may comprise a retinoid selected from the group of naturally occurring retinoids such as Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners. These would include but not be limited to the isomers all trans; 9-cis; 11-cis; 13-cis; 9, 11-dicis, and 11, 13-dicis as well as physiologically compatible ethers, esters, amides and salts thereof. The 7, 8-dihydro and 5,6-dihydro congeners as well as etretinate are also acceptable for the invention.

Compounds that intrinsically or upon metabolism possess the physiologic properties of retinoids are also included within the scope of this invention. These would include synthetic and natural retinoid compounds having affinity to
5 nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs).

Importantly, the present invention encompasses a method for improving biocompatibility of a surgically implantable
10 prosthesis with the method comprising the step of combining a retinoid with the prosthesis. More particularly, the step may include disposing a film of retinoid on the prosthesis or, embedding retinoid, to the surface of the prosthesis. The
15 retinoid may comprise a retinoid, as hereinabove noted, and be selected from the group of naturally occurring retinoids such as Vitamin A (retinol), vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners. These would include but not be limited to the
20 isomers all trans; 9-cis; 11-cis; 13-cis; 9,11-dicis, and 11,13-dicis as well as physiologically compatible ethers, esters, amides and salts thereof. The 7, 8-dihydro and 5,6-dihydro congeners as well as etretinate are also acceptable for the invention.

Compounds that intrinsically or upon metabolism possess the physiologic properties of retinoids are also included within the scope of this invention. These would include
25 synthetic and natural retinoid compounds having affinity to nuclear retinoic acid receptors (RARs) and retinoid X
30 receptors (RXRs).

BRIEF DESCRIPTION OF THE DRAWINGS

The advantages and features of the present invention will be better understood by the following description when

considered in conjunction with the accompanying drawings in which:

Figure 1 is an implantable device in accordance with the one embodiment of the present invention, specifically a retinal plug, for providing local delivery to the intraocular tissues of a therapeutic agent;

Figure 2 is a diagram showing the positioning of the retinal plug shown in Figure 1 in an eye through the sclera and pars plana;

Figure 3 is a perspective view of an alternative embodiment in accordance with the present invention, specifically a surgically implantable prosthesis such as a cardiac valve component coated with a film of retinoid;

Figure 4 is a drawing showing the encapsulation of a placebo plug 28 days after insertion into the vitreous through sclera. The plug is comprised of polylactic acid. The plug disappears during the processing of the eye (A). The tissues surrounding the plug were stained with PAS and show a fibrous capsule surrounding the area (B) where the placebo was previously located. The capsule that surrounded the polylactic acid plug shows a very prominent inflammatory response with inflammatory cell infiltration (C); and

Figure 5 is a drawing showing the encapsulation of a retinoid containing plug 28 days after insertion. The polylactic acid plug contained 10% by weight of the retinoid 6-[(4,4-dimethyl thiochroman-6-yl) ethynyl] nicotinic acid (AGN 190299). The plug disappears in the processing of the eye (A). The tissues surrounding the retinoid containing plug were stained with PAS. The figure shows that the capsule

surrounding the AGN190299 plug (B) has very little fibrous inflammation (C).

DETAILED DESCRIPTION

5

Turning to Figures 1 and 2, there is shown an implantable device 10 for providing systemic release of a therapeutic agent in tissue. Device 10 is representative of a great number of devices for systemic release of a therapeutic agent. 10 This specific embodiment 10 is a sterile, bioerodible plug for the intraocular delivery of pharmaceutically active compounds. Placement of the device 10 is illustrated in Figure 2 as it may be inserted into an eye 12 specifically, the sclera 14 proximate the lens 16 and iris 18 for release of the drug into 15 the sclera, choroid, retina and vitreous cavity. By way of example, the retinal plug, or device, 10, may have a weight of about 0.5 to about 10 milligrams, have a diameter of about 0.5 and about 2 millimeters and a length of between one and 12 millimeters. A hole 20 through a proximal end 22 of the 20 device 10 enables a suture 24 to be used for securing the device 10, as shown in Figure 2, with a distal end 26 thereof protruding into a vitreous cavity 30.

Any suitable therapeutic agent may be utilized. The 25 diversity of therapeutic agents that can be delivered by the present invention is great and known to those skilled in the art. Examples include but are not limited to antibiotics, antifungals and antivirals such as erythromycin, tetracycline, aminoglycosides, cephalosporins, quinolones, penicilins, 30 sulfonamides, ketoconazole, miconazole, acyclovir, ganciclovir, azidothymidine, interferon; anticonvulsants such as phenytoin and valproic acid; antidepressants such as amitriptyline and trazodone; antiparkinsonism drugs; cardiovascular agents such as calcium channel blockers, 35 antiarrhythmics, beta blockers; antineoplastics such as

cisplatin and methotrexate, corticosteroids such as dexamethasone, hydrocortisone, prednisolone, and triamcinolone; NSAIDs such as ibuprofen, salicylates indomethacin, piroxicam; Hormones such as progesterone, 5 estrogen, testosterone; growth factors; carbonic anhydrase inhibitors such as acetazolamide; prostaglandins; antiangiogenic agents; neuroprotectants; other drugs known to those skilled in the art to benefit from controlled or sustained release from implantable devices or combinations 10 thereof.

These active agents may be incorporated into a bioerodible polymer such as a poly ester, poly (ortho ester), poly (phosphazine), poly (phosphate ester), poly-caprolactone, 15 poly (hydroxybutyric acid), natural polymer such as gelatine or collagen, or a polymeric blend. In addition, the present invention may also improve the biocompatibility of non-erodible polymeric implants.

20 Importantly, a retinoid is incorporated into the device 10 for improving the biocompatibility thereof. All of the components of the device 10 are extruded as a homogeneous system in the shape of a plug.

25 The device 10 may be optimized to resist sclera and choroidal erosion in order to prevent disintegration or fragmentation of the plug 10 into the vitreous cavity 30. This may be accomplished, as is well known in the art, by altering the surface, finish of the plug 10, coating the plug 30 with another biodegradable semipermeable polymer, or the addition of another polymer to the blend. Because the plug is a homogeneous system, ease of manufacture is provided through simple extrusion techniques or injection molding.

The mechanism and rate of drug release may be controlled by the choice polymer, polymer molecular weight, polymer crystallinity, copolymer ratios, processing conditions, surface finish, geometry, excipient addition, and polymeric coatings, with the drug being released from the device 10 by diffusion, erosion, dissolution or osmosis.

The fabrication of various sclera plugs and the mechanism of controlling the drug release is well known in the art as 10 set forth in numerous publications such as, for example, "Sclera Plug of Biodegradable Polymers for Controlling Drug Release in Vitreous", Mototane Hashizoe, Archophthalmol/Volume 112, page 1380-1384, October, 1994; "A New Vitreal Drug Delivery Systems Using an Implantable Biodegradable Polymeric 15 Device", Hideya Kimura et al, Investigative Ophthalmology and Visual Science, Volume 35, page 2815-2819, May, 1994, and U.S. Patent No 5,466,233, all of which are incorporated herein in their entirety for the purpose of describing sclera plug manufacture, use and mechanisms.

20

All of the active ingredients utilized in the plug device 10 are present in a therapeutic effective amount which is calculated to achieve and maintain a therapeutic level in the vitreous cavity and introduced by the vitreous plug. 25 Naturally, the therapeutic amount will vary with the potency of the active agent, the rate of release by the plug device 10.

The amount of incorporated retinoid will depend on the 30 potency and receptor selectivity of the retinoid employed as well as the release rate of the retinoid from the specific implant. Typically, the amount of retinoid employed represents 0.001% to 50%, more typically from 0.01 to 20%

Retinoic acid receptor agonists have been utilized for preventing proliferation of retinal pigment epithelium, see copending U.S. Patent Application S.N. 08/383,741, entitled "Method of Preventing Proliferation of Retinal
5 Pigment of Epithelium by Retinoic Acid Receptor Agonists", filed in the name of Campochiaro and is to be incorporated herewith in its entirety for describing the use of retinoic acid activity in the vitreous cavity 30.

10 Importantly, it has been discovered that the use of retinoids can improve the biocompatibility of the device 10 in tissue. While the retinoid may be incorporated into the device as a component of the homogeneous mass, as hereinabove described in connection with the plug device 10, the retinoid
15 may also be used to advantage for improving biocompatibility when disposed as a film 40 on an implanted device 42 as shown in Figure 3. The device 42 is a component for a cardiac valve as is described in U.S. Patent No. 5,370,684 which is to be incorporated herewith in its entirety in describing typical
20 implantable devices 42 suitable in combination with the retinoid for improving biocompatibility thereof. In addition, this patent is to be incorporated herein by the specific reference thereto for the purpose of coating or embedding techniques suitable for bonding the retinoid to the surface 44
25 of the implant 42.

When applied as a film 40 or imbedded into a surface 44 of the implant 42, the retinoid may be incorporated in amounts depending on the potency and receptor selectivity of
30 the retinoid employed as well as the release rate of the retinoid from the specific implant.

Typically, the amount of retinoid employed represents 0.001% to 50%, more typically from 0.01 to 20%.

The retinoid may be either naturally occurring or a synthetic retinoid such as a retinoic acid receptor (RAR) agonist.

5 Naturally occurring retinoids suitable for use in the present invention includes naturally occurring retinoids such as Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners. These would include but not be limited to the
10 isomers all trans; 9-cis; 11-cis; 13-cis; 9,11-dicis, and 11,13-dicis as well as physiologically compatible ethers, esters, amides and salts thereof. the 7,8-dihydro and 5,6-dihydro congeners as well as etretinate are also acceptable for the invention.

15

Compounds that intrinsically or upon metabolism possess the physiologic properties of retinoids are also included within the scope of this invention. These would include synthetic and natural retinoid compounds having affinity to
20 nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs).

Other synthetically prepared retinoids are also well
25 known in the art. For example, see U.S. Patent No. 5,234,926 which is incorporated here by reference thereto in its entirety which discloses methods of synthesizing disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups with a selective activity as RAR agonists. U.S. Patent No.
30 4,326,055 is incorporated herewith by reference thereto in its entirety for disclosing methods for synthesizing 5, 6, 7, 8-tetrahydro naphthal and indanyl stilbene derivatives with retinoid-like activity.

Examples of synthetic agonists suitable for use in the practice of this invention are ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate (Compound 168) and 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinic acid (Compound 299), whose synthesis is disclosed in U.S. Patent No. 5,234,926 as Examples 6 and 24, respectively; and p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid (Compound 183), whose synthesis is disclosed in U.S. Patent No. 4,326,055, and 2-[(E)-2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)propen-1-yl]thiophene-4-carboxylic acid (Compound 701), whose synthesis is disclosed in U.S. Patent No. 5,324,840, Example 11.

Alternatively, the sclera plug 10, while being generally homogeneous, may include a film 50 of retinoid thereon in order to improve biocompatibility in a manner similar to the improved biocompatibility of a non-bioerodible device 42 such as shown in Figure 3.

Accompanying the hereinabove described devices is a method in accordance with the present invention for improving the biocompatibility of an implant in tissue which includes the step of providing a therapeutic agent, providing a carrier sized for insertion into the tissue in which the release of a therapeutic agent is desired, incorporating the therapeutic agent into a carrier in a manner enabling the time released of the therapeutic agent and incorporating the retinoid into the carrier in an amount effective for improving the biocompatibility of a carrier in the tissue. This method, of course, corresponds to the device 10 shown in Figures 1 and 2.

Correspondingly, a method in accordance with the present invention relating to the device 42 shown in Figure 3 include combining the retinoid 40 with the prosthesis 42. This method

may include the deposition of a film 40 on the prosthesis 42 or imbedding the retinoid into surface 44 of the prosthesis. All of the hereinabove recited retinoids may be used in accordance with the method of the present invention.

5

The following example illustrates the effectiveness of the method and devices of the present invention. It should be appreciated that the example is set forth herein for the purpose of illustration only and is not to be regarded as
10 limiting to any of the specific materials or methods disclosed.

EXAMPLE 1

15 An implantable device 10 was prepared as follows:

Retinal plugs were manufactured from poly(D,L)lactic acid (PLA) with an intrinsic viscosity of 0.6DL/G. The retinoid 6-[(4,4-dimethyl thiochroman-6-yl) ethynl] nicotinic acid
20 (AGN190299) was mixed with polymer in a three-dimensional mixer. The mixture was then extruded at 85°C into a homogeneous rod. The retinoid was incorporated into the polymeric plug at a concentration of 10%. The extruded plug was then cut to a length of 3.0 mm and had a diameter of 1.5
25 mm. A 0.5 mm hole was drilled into the distal end of the plug to allow for suture fixation to the sclera. Placebo plugs containing no retinoid were also manufactured to the same dimensions. The average weight of the plugs was 8 mg. All plugs were sterilized by gamma irradiation at 1 Mrad.

30

The plugs were then implanted into pigmented rabbits as shown in Figure 2. The rabbit eyes were vitrectomized and the retinal plugs with or without incorporated retinoid were inserted through a sclerotomy 3 mm posterior to the
35 corneoscleral limbus. The plugs were then fixated with the

suture used to close the sclerotomy. An intravitreal injection of 500,000 human RPE cells was given to simulate traction retinal detachment. The rabbits were sacrificed at 28 days and histopathology was done.

5

These observed results are shown in Figure 4 for the placebo plug and in Figure 5 for the plug 10 including the retinoid as hereinabove described.

10 Figure 4 is a drawing showing the encapsulation of a placebo plug 28 days after insertion into the vitreous through the sclera. The plug is comprised of polylactic acid. The plug disappears during the processing of the eye (A). The tissues surrounding the plug were stained with PAS and show a
15 fibrous capsule surrounding the area (B) where the placebo was previously located. The capsule that surrounded the polylactic acid plug shows a very prominent inflammatory response with inflammatory cell infiltration (C).

20 Figure 5 is a drawing showing the encapsulation of a retinoid containing plug 28 days after insertion. The polylactic acid plug contain 10% by weight of the retinoid 6-[(4,4-dimethyl thiochroman-6-yl) ethynyl] nicotinic acid (AGN190299). The plug disappears in the processing of the eye
25 (A). The tissues surrounding the retinoid containing plug were stained with PAS. The figure shows that the capsule surrounding the AGN190299 plug (B) has very little fibrous inflammation (C).

30 Although there has been hereinabove described a particular arrangement of implantable devices and methods in accordance with the present invention, for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not
35 limited thereto. Accordingly, any and all modifications,

variations or equivalent arrangements which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.

WHAT IS CLAIMED IS:

1. An implantable device for providing systemic or local release of a therapeutic agent in tissue, the device comprising:
 - a therapeutic agent;
 - 5 a carrier sized for insertion into tissue in which systemic release of the therapeutic agent is desired, said carrier including means for providing controlled release of the therapeutic agent; and
 - retinoid means, present in said carrier, for improving biocompatibility of said device in said tissue.
2. The device according to claim 1 wherein said retinoid means comprises a retinoid receptor agonist.
3. The device according to claim 2 wherein said therapeutic agent, carrier and retinoid means are homogeneous.
4. The device according to claim 3 wherein said means for providing controlled release of the therapeutic agent comprises a biodegradable polymer.
5. The device according to claim 4 wherein said biodegradable polymer comprises a poly (lactic acid).
6. The device according to claim 4 wherein said biodegradable polymer comprises poly (lactide-co-glycolide).
7. The device according to claim 4 wherein said carrier is sized for implanting into a sclera.
8. The device according to claim 2 wherein said retinoid receptor agonist comprises a naturally occurring retinoid.

9. The device according to claim 2 wherein said retinoid receptor agonist is selected from a group consisting of Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.

10. The device according to claim 2 wherein the retinoid receptor agonist comprises ethyl - 6 - [2 - (4, 4 - dimethylthiochroman-6-yl) ethynyl] nicotinate.

11. The device according to claim 2 wherein the retinoid receptor agonist comprises ethyl - 6 - [2 - (4, 4 - dimethylthiochroman-6-yl) ethynyl] nicotinate.

12. The device according to claim 2 wherein the retinoid receptor agonist comprises p-[(E) -2- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl) propenyl]-benzoic acid.

13. An implantable device for providing systemic or local release of a therapeutic agent in tissue, the device comprising:

a carrier sized for insertion into tissue in which systemic or local release of a therapeutic agent is desired, said carrier including means for providing controlled release of the therapeutic agent; and

retinoid means, present in said carrier as the therapeutic agent, for improving biocompatibility of said device in said tissue.

14. The device according to claim 13 wherein said retinoid means comprises a retinoid receptor agonist.

15. The device according to claim 13 wherein said carrier and retinoid means are homogeneous.

16. The device according to claim 15 wherein aid means for providing controlled release of the therapeutic agent comprises a biodegradable polymer.

17. The device according to claim 16 wherein said biodegradable polymer comprises a poly (lactic acid).
18. The device according to claim 16 wherein said biodegradable polymer comprises a poly (lactide-co-glycolide).
19. The device according to claim 16 wherein said carrier is sized for implanting into a sclera.
20. The device according to claim 17 wherein said retinoid receptor comprises a naturally occurring retinoid.
21. A method for improving biocompatibility of an implant in tissue, the method comprising the steps of:
- providing a therapeutic agent;
 - providing a carrier sized for insertion into tissue in which release of
 - 5 said therapeutic agent is desired;
 - incorporating the therapeutic agent into said carrier in a manner enabling controlled release of said therapeutic agent; and
 - incorporating a retinoid into said carrier in an amount effective for improving biocompatibility of said carrier in said tissue.
22. The method according to claim 21 wherein said retinoid comprises a naturally occurring retinoid.
23. The method according to claim 21 wherein said retinoid is selected from a group consisting of Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.
24. A method for improving biocompatibility of an implant in tissue, the method comprising:

providing a carrier sized for insertion into tissue in which release of a therapeutic agent is desired; and

- 5 incorporating into said carrier as the therapeutic agent in a retinoid in an amount effective for improving biocompatibility of said carrier in said tissue.

25. The method according to claim 24 wherein said retinoid comprises a naturally occurring retinoid.

26. The method according to claim 24 wherein said retinoid is selected from a group consisting of Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.

27. A method for improving biocompatibility of an implant in tissue comprising incorporating a retinoid into said implant.

28. The method according to claim 27 wherein said retinoid comprises naturally occurring retinoids.

29. An implantable device comprising:
a surgically implantable prosthesis; and, in combination therewith, retinoid means for improving biocompatibility of the prosthesis.

30. The device according to claim 29 wherein said retinoid means is present in the form of a film on the prosthesis.

31. The device according to claim 30 wherein said retinoid means is bonded to a surface of the prosthesis.

32. The device according to claim 29 wherein said retinoid means comprises a naturally occurring retinoid.

33. The device according to claim 29 wherein said retinoid means is selected from a group consisting of Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.

34. A method for improving biocompatibility of a surgically implantable prosthesis, the method comprising combining a retinoid with the prosthesis.

35. The method according to claim 34 wherein the step of combining the retinoid includes disposing a film of retinoid on the prosthesis.

36. The method according to claim 34 wherein the step of combining the retinoid includes embedding retinoid into surfaces of the prosthesis.

37. The method according to claim 34 wherein the retinoid comprises a naturally occurring retinoid.

38. The method according to claim 34 wherein the retinoid is selected from a group of Vitamin A (retinol), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.

39. The method according to claim 34 wherein the retinoid comprises ethyl -6 - [2-(4, 4-dimethylthiochroman-6-yl) ethynyl] nicotinate.

40. The method according to claim 34 wherein the retinoid comprises 6 - [2 - (4, 4-dimethylchroman-6-yl) ethynyl] nicotinic acid.

41. The device according to claim 34 wherein the retinoid comprises p-[(E) -2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl) propenyl]-benzoic acid.




FIG. 1.




FIG. 2.




FIG. 3.



FIG. 4.



FIG. 5.